Troglitazone activates p21Cip/WAF1 through the ERK pathway in HCT15 human colorectal cancer cells

被引:28
作者
Kim, JA
Park, KS
Kim, HI
Oh, SY
Ahn, Y
Oh, JW
Choi, KY [1 ]
机构
[1] Yonsei Univ, Dept Biochem & Mol Biol, Coll Med, Seoul 120749, South Korea
[2] Yonsei Univ, Coll Engn, Dept Biotechnol, Seoul 120752, South Korea
关键词
troglitazone; ERK; p21(Cip/WAF1); cell cycle; anti-cancer;
D O I
10.1016/S0304-3835(01)00869-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In this study, we identified a new mechanism for the anti-proliferation of HCT15 colorectal cancer cells by troglitazone (TRO). Treating HCT15 cells with 20 muM of TRO transiently increased extracellular signal regulated kinase (ERK) activity within 15 min, and this subsequently induced p21(Cip/WAF1) cell cycle regulator and localized in the nucleus. Raf-1 modification and MEK activation also occurred after TRO treatment, and Elk-l-dependent trans-reporter gene expression was concomitantly induced. The induction and nuclear localization of p21(Cip/WAF1) by TRO were blocked by PD98059 pre-treatment, which suggested a role for the ERK pathway in p21(Cip/WAF1) activation. TRO inhibited BrdU incorporation and no BrdU incorporation was observed in most p21(Cip/WAF1)-activated cells. Therefore, TRO regulates the proliferation of HCT15 cells at least partly by a mechanism involving the activation of p21(Cip/WAF1). (C) 2002 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:185 / 195
页数:11
相关论文
共 26 条
[1]   PD-098059 IS A SPECIFIC INHIBITOR OF THE ACTIVATION OF MITOGEN-ACTIVATED PROTEIN-KINASE KINASE IN-VITRO AND IN-VIVO [J].
ALESSI, DR ;
CUENDA, A ;
COHEN, P ;
DUDLEY, DT ;
SALTIEL, AR .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (46) :27489-27494
[2]   p21WAF1 is required for butyrate-mediated growth inhibition of human colon cancer cells [J].
Archer, SY ;
Meng, SF ;
Shei, A ;
Hodin, RA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (12) :6791-6796
[3]   MUTATOR PHENOTYPES IN HUMAN COLORECTAL-CARCINOMA CELL-LINES [J].
BHATTACHARYYA, NP ;
SKANDALIS, A ;
GANESH, A ;
GRODEN, J ;
MEUTH, M .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (14) :6319-6323
[4]  
BOS JL, 1989, CANCER RES, V49, P4682
[5]   MEK inhibitors: The chemistry and biological activity of U0126, its analogs, and cyclization products [J].
Duncia, JV ;
Santella, JB ;
Higley, CA ;
Pitts, WJ ;
Wityak, J ;
Frietze, WE ;
Rankin, FW ;
Sun, JH ;
Earl, RA ;
Tabaka, AC ;
Teleha, CA ;
Blom, KF ;
Favata, MF ;
Manos, EJ ;
Daulerio, AJ ;
Stradley, DA ;
Horiuchi, K ;
Copeland, RA ;
Scherle, PA ;
Trzaskos, JM ;
Magolda, RL ;
Trainor, GL ;
Wexler, RR ;
Hobbs, FW ;
Olson, RE .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1998, 8 (20) :2839-2844
[6]   WAF1, A POTENTIAL MEDIATOR OF P53 TUMOR SUPPRESSION [J].
ELDEIRY, WS ;
TOKINO, T ;
VELCULESCU, VE ;
LEVY, DB ;
PARSONS, R ;
TRENT, JM ;
LIN, D ;
MERCER, WE ;
KINZLER, KW ;
VOGELSTEIN, B .
CELL, 1993, 75 (04) :817-825
[7]   The effects of thiazolidinediones on vascular smooth muscle cell activation by angiotensin II [J].
Hattori, Y ;
Akimoto, K ;
Kasai, K .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2000, 273 (03) :1144-1149
[8]   ETS-RELATED PROTEIN ELK-1 IS HOMOLOGOUS TO THE C-FOS REGULATORY FACTOR P62TCF [J].
HIPSKIND, RA ;
RAO, VN ;
MUELLER, CGF ;
REDDY, ESP ;
NORDHEIM, A .
NATURE, 1991, 354 (6354) :531-534
[9]   The MEK pathway is required for stimulation of p21WAF1/CIP1 by transforming growth factor-β [J].
Hu, PPC ;
Shen, X ;
Huang, D ;
Liu, YY ;
Counter, C ;
Wang, XF .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (50) :35381-35387
[10]  
JANES PW, 1994, ONCOGENE, V9, P3601